{"transactions":[{"id":681867,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681866,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested and exercisable."}],"balance_after":5000,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681865,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":900,"price":63.8557,"value":57470.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":61500,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681864,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":4100,"price":63.2659,"value":259390.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":62400,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681863,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":17.44,"value":87200.0,"ownership":{"direct":true},"balance_after":66500,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681862,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":500,"price":64.162,"value":32081.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":61500,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681861,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":2600,"price":63.4999,"value":165099.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":62000,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681860,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":62.5289,"value":118804.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":64600,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681859,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":17.44,"value":87200.0,"ownership":{"direct":true},"balance_after":66500,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":759325,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2026-05-29T22:04:49.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in 12 monthly installments beginning June 27, 2026."}],"balance_after":2624,"derivative":{"exercise_price":155.83,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":2624},"source":{"system":"sec-edgar","filing":"0001123343-26-000008","document":"wk-form4_1780092285.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112334326000008/wk-form4_1780092285.xml","form_type":"4"}},{"id":759324,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:04:49.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":1284,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":1284,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1284},"source":{"system":"sec-edgar","filing":"0001123343-26-000008","document":"wk-form4_1780092285.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112334326000008/wk-form4_1780092285.xml","form_type":"4"}},{"id":768845,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-21T23:21:01.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":1659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1659},"source":{"system":"sec-edgar","filing":"0001123343-26-000006","document":"wk-form4_1779405659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112334326000006/wk-form4_1779405659.xml","form_type":"4"}},{"id":768844,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T23:21:01.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":true,"shares":1659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"116,158 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power"}],"balance_after":122141,"source":{"system":"sec-edgar","filing":"0001123343-26-000006","document":"wk-form4_1779405659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112334326000006/wk-form4_1779405659.xml","form_type":"4"}},{"id":768487,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-05-21T21:00:14.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":12000,"derivative":{"exercise_price":42.26,"exercise_date":"2027-05-19","expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001123343-26-000004","document":"form4-05212026_050508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000004/form4-05212026_050508.xml","form_type":"4"}},{"id":768486,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T21:00:14.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":61500,"source":{"system":"sec-edgar","filing":"0001123343-26-000004","document":"form4-05212026_050508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000004/form4-05212026_050508.xml","form_type":"4"}},{"id":807437,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-04-16T20:05:17.000Z","date":"2026-04-14","kind":"exercise","planned":true,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":16.33,"expiration_date":"2026-05-18","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001123343-26-000002","document":"form4-04162026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000002/form4-04162026_040407.xml","form_type":"4"}},{"id":807436,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-16T20:05:17.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":8000,"price":41.07,"value":328560.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on November 11, 2025 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 18, 2026."}],"balance_after":57500,"source":{"system":"sec-edgar","filing":"0001123343-26-000002","document":"form4-04162026_040407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000002/form4-04162026_040407.xml","form_type":"4"}},{"id":807435,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-16T20:05:17.000Z","date":"2026-04-14","kind":"exercise","planned":true,"acquired":true,"shares":8000,"price":16.33,"value":130640.0,"ownership":{"direct":true},"balance_after":65500,"source":{"system":"sec-edgar","filing":"0001123343-26-000002","document":"form4-04162026_040407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000002/form4-04162026_040407.xml","form_type":"4"}},{"id":980707,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-12-04T21:14:05.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026."}],"balance_after":0,"derivative":{"exercise_price":47.89,"expiration_date":"2026-05-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001123343-25-000006","document":"wk-form4_1764882842.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112334325000006/wk-form4_1764882842.xml","form_type":"4"}},{"id":980706,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-04T21:14:05.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":152.6055,"value":2289082.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.63 to $154.34. The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"114,499 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":120482,"source":{"system":"sec-edgar","filing":"0001123343-25-000006","document":"wk-form4_1764882842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112334325000006/wk-form4_1764882842.xml","form_type":"4"}},{"id":980705,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-04T21:14:05.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":47.89,"value":718350.0,"ownership":{"direct":true},"balance_after":135482,"source":{"system":"sec-edgar","filing":"0001123343-25-000006","document":"wk-form4_1764882842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112334325000006/wk-form4_1764882842.xml","form_type":"4"}},{"id":1138134,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-22T21:18:15.000Z","date":"2025-05-22","kind":"exercise","planned":false,"acquired":false,"shares":1435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1435},"source":{"system":"sec-edgar","filing":"0000914475-25-000127","document":"wk-form4_1747948689.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000127/wk-form4_1747948689.xml","form_type":"4"}},{"id":1138133,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-05-22T21:18:15.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":3305,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option vests in 12 monthly installments beginning June 21, 2025."}],"balance_after":3305,"derivative":{"exercise_price":120.56,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":3305},"source":{"system":"sec-edgar","filing":"0000914475-25-000127","document":"wk-form4_1747948689.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000127/wk-form4_1747948689.xml","form_type":"4"}},{"id":1138132,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-22T21:18:15.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":1659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest in full on May 21, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest in full on May 21, 2026."}],"balance_after":1659,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1659},"source":{"system":"sec-edgar","filing":"0000914475-25-000127","document":"wk-form4_1747948689.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000127/wk-form4_1747948689.xml","form_type":"4"}},{"id":1138131,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T21:18:15.000Z","date":"2025-05-22","kind":"exercise","planned":false,"acquired":true,"shares":1435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"114,499 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power"}],"balance_after":120482,"source":{"system":"sec-edgar","filing":"0000914475-25-000127","document":"wk-form4_1747948689.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000127/wk-form4_1747948689.xml","form_type":"4"}},{"id":1145903,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-05-16T23:00:12.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":19500,"derivative":{"exercise_price":21.15,"exercise_date":"2026-05-15","expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001415889-25-013499","document":"form4-05162025_070509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000141588925013499/form4-05162025_070509.xml","form_type":"4"}},{"id":1145902,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-16T23:00:12.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":57500,"source":{"system":"sec-edgar","filing":"0001415889-25-013499","document":"form4-05162025_070509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000141588925013499/form4-05162025_070509.xml","form_type":"4"}},{"id":1390951,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-10-04T23:15:51.000Z","date":"2024-10-04","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":10.48,"expiration_date":"2024-10-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-024795","document":"form4-10042024_111048.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000141588924024795/form4-10042024_111048.xml","form_type":"4"}},{"id":1390950,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T23:15:51.000Z","date":"2024-10-04","kind":"sale","planned":true,"acquired":false,"shares":18821,"price":15.1547,"value":285226.6087,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on March 16, 2023 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $15.1547, and the range of prices were between $14.92 and $15.44.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001415889-24-024795","document":"form4-10042024_111048.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000141588924024795/form4-10042024_111048.xml","form_type":"4"}},{"id":1390949,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T23:15:51.000Z","date":"2024-10-04","kind":"sale","planned":true,"acquired":false,"shares":21179,"price":14.3479,"value":303874.1741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on March 16, 2023 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.3479, and the range of prices were between $13.92 and $14.91.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":69821,"source":{"system":"sec-edgar","filing":"0001415889-24-024795","document":"form4-10042024_111048.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000141588924024795/form4-10042024_111048.xml","form_type":"4"}},{"id":1390948,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T23:15:51.000Z","date":"2024-10-04","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":10.48,"value":419200.0,"ownership":{"direct":true},"balance_after":91000,"source":{"system":"sec-edgar","filing":"0001415889-24-024795","document":"form4-10042024_111048.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000141588924024795/form4-10042024_111048.xml","form_type":"4"}},{"id":1432949,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2024-08-15T21:21:58.000Z","date":"2024-08-13","kind":"exercise","planned":true,"acquired":false,"shares":11570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025."}],"balance_after":0,"derivative":{"exercise_price":42.76,"expiration_date":"2025-05-28","underlying":"Common Stock","underlying_shares":11570},"source":{"system":"sec-edgar","filing":"0000914475-24-000195","document":"wk-form4_1723756911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000195/wk-form4_1723756911.xml","form_type":"4"}},{"id":1432948,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-15T21:21:58.000Z","date":"2024-08-13","kind":"sale","planned":true,"acquired":false,"shares":11570,"price":150.4278,"value":1740449.646,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $151.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":119047,"source":{"system":"sec-edgar","filing":"0000914475-24-000195","document":"wk-form4_1723756911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000195/wk-form4_1723756911.xml","form_type":"4"}},{"id":1432947,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-15T21:21:58.000Z","date":"2024-08-13","kind":"exercise","planned":true,"acquired":true,"shares":11570,"price":42.76,"value":494733.2,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":130617,"source":{"system":"sec-edgar","filing":"0000914475-24-000195","document":"wk-form4_1723756911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000195/wk-form4_1723756911.xml","form_type":"4"}},{"id":1452080,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2024-07-18T20:54:02.000Z","date":"2024-07-16","kind":"exercise","planned":true,"acquired":false,"shares":930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025."}],"balance_after":11570,"derivative":{"exercise_price":42.76,"expiration_date":"2025-05-28","underlying":"Common Stock","underlying_shares":930},"source":{"system":"sec-edgar","filing":"0000914475-24-000172","document":"wk-form4_1721336035.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000172/wk-form4_1721336035.xml","form_type":"4"}},{"id":1452079,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-18T20:54:02.000Z","date":"2024-07-16","kind":"sale","planned":true,"acquired":false,"shares":930,"price":150.0325,"value":139530.225,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.18. The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":119047,"source":{"system":"sec-edgar","filing":"0000914475-24-000172","document":"wk-form4_1721336035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000172/wk-form4_1721336035.xml","form_type":"4"}},{"id":1452078,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-18T20:54:02.000Z","date":"2024-07-16","kind":"exercise","planned":true,"acquired":true,"shares":930,"price":42.76,"value":39766.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":119977,"source":{"system":"sec-edgar","filing":"0000914475-24-000172","document":"wk-form4_1721336035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000172/wk-form4_1721336035.xml","form_type":"4"}},{"id":1504409,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2024-05-23T22:17:56.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":2982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in 12 monthly installments beginning June 22, 2024."}],"balance_after":2982,"derivative":{"exercise_price":139.43,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":2982},"source":{"system":"sec-edgar","filing":"0000914475-24-000146","document":"wk-form4_1716502667.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000146/wk-form4_1716502667.xml","form_type":"4"}},{"id":1504408,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-23T22:17:56.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":1435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 22, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 22, 2025."}],"balance_after":1435,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1435},"source":{"system":"sec-edgar","filing":"0000914475-24-000146","document":"wk-form4_1716502667.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000146/wk-form4_1716502667.xml","form_type":"4"}},{"id":1507786,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-21T20:57:26.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":false,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2100},"source":{"system":"sec-edgar","filing":"0000914475-24-000129","document":"wk-form4_1716325029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000129/wk-form4_1716325029.xml","form_type":"4"}},{"id":1507785,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T20:57:26.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":true,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"110,964 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":119047,"source":{"system":"sec-edgar","filing":"0000914475-24-000129","document":"wk-form4_1716325029.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000129/wk-form4_1716325029.xml","form_type":"4"}},{"id":1514999,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2024-05-16T20:55:21.000Z","date":"2024-05-14","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":42.76,"value":534500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025."}],"balance_after":12500,"derivative":{"exercise_price":42.76,"expiration_date":"2025-05-28","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000914475-24-000123","document":"wk-form4_1715892908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000123/wk-form4_1715892908.xml","form_type":"4"}},{"id":1514998,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T20:55:21.000Z","date":"2024-05-14","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":135.6296,"value":1695370.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $134.78 to $137.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"110,964 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":116947,"source":{"system":"sec-edgar","filing":"0000914475-24-000123","document":"wk-form4_1715892908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000123/wk-form4_1715892908.xml","form_type":"4"}},{"id":1514997,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T20:55:21.000Z","date":"2024-05-14","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":42.76,"value":534500.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Reflects a decrease of 76,750 shares from the amount previously reported as beneficially owned, which was recently discovered to be overstated due to an administrative oversight."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"110,964 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":129447,"source":{"system":"sec-edgar","filing":"0000914475-24-000123","document":"wk-form4_1715892908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000123/wk-form4_1715892908.xml","form_type":"4"}},{"id":1521018,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-05-10T20:05:45.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":19500,"derivative":{"exercise_price":6.82,"exercise_date":"2025-05-08","expiration_date":"2034-05-07","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001415889-24-012847","document":"form4-05102024_040530.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000141588924012847/form4-05102024_040530.xml","form_type":"4"}},{"id":1521017,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-10T20:05:45.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001415889-24-012847","document":"form4-05102024_040530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000141588924012847/form4-05102024_040530.xml","form_type":"4"}},{"id":1699787,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T21:10:42.000Z","date":"2023-12-22","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":130.0443,"value":1300443.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":193697,"source":{"system":"sec-edgar","filing":"0001209191-23-059771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123059771/doc4.xml","form_type":"4"}},{"id":1722701,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-05T21:54:39.000Z","date":"2023-12-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":12.98,"value":64900.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted May 22, 2014 and vested monthly over one year."}],"balance_after":0,"derivative":{"exercise_price":12.98,"expiration_date":"2024-05-22","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000914475-23-000080","document":"wk-form4_1701813271.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000080/wk-form4_1701813271.xml","form_type":"4"}},{"id":1722700,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T21:54:39.000Z","date":"2023-12-01","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":116.7674,"value":583837.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.06 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":203697,"source":{"system":"sec-edgar","filing":"0000914475-23-000080","document":"wk-form4_1701813271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000080/wk-form4_1701813271.xml","form_type":"4"}},{"id":1722699,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T21:54:39.000Z","date":"2023-12-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":12.98,"value":64900.0,"ownership":{"direct":true},"balance_after":208697,"source":{"system":"sec-edgar","filing":"0000914475-23-000080","document":"wk-form4_1701813271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000080/wk-form4_1701813271.xml","form_type":"4"}},{"id":1781359,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2023-09-14T20:51:50.000Z","date":"2023-09-12","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":12.98,"value":64900.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted May 22, 2014 and vested monthly over one year."}],"balance_after":5000,"derivative":{"exercise_price":12.98,"expiration_date":"2024-05-22","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-23-049448","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123049448/doc4.xml","form_type":"4"}},{"id":1781358,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-14T20:51:50.000Z","date":"2023-09-12","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":115.024,"value":575120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.00 to $115.22. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":203697,"source":{"system":"sec-edgar","filing":"0001209191-23-049448","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123049448/doc4.xml","form_type":"4"}},{"id":1781357,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-14T20:51:50.000Z","date":"2023-09-12","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":12.98,"value":64900.0,"ownership":{"direct":true},"balance_after":208697,"source":{"system":"sec-edgar","filing":"0001209191-23-049448","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123049448/doc4.xml","form_type":"4"}},{"id":1787964,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2023-09-06T20:25:23.000Z","date":"2023-09-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":12.98,"value":64900.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted May 22, 2014 and vested monthly over one year."}],"balance_after":10000,"derivative":{"exercise_price":12.98,"expiration_date":"2024-05-22","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-23-048383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123048383/doc4.xml","form_type":"4"}},{"id":1787963,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-06T20:25:23.000Z","date":"2023-09-01","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":110.0631,"value":550315.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":203697,"source":{"system":"sec-edgar","filing":"0001209191-23-048383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123048383/doc4.xml","form_type":"4"}},{"id":1787962,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-06T20:25:23.000Z","date":"2023-09-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":12.98,"value":64900.0,"ownership":{"direct":true},"balance_after":208697,"source":{"system":"sec-edgar","filing":"0001209191-23-048383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123048383/doc4.xml","form_type":"4"}},{"id":1831088,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-12T22:45:31.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":1.32,"expiration_date":"2033-05-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-23-034287","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123034287/form4.xml","form_type":"4"}},{"id":1831087,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-12T22:45:31.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001140361-23-034287","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123034287/form4.xml","form_type":"4"}},{"id":1885689,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-05-19T21:15:18.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest in full on May 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest in full on May 17, 2024."}],"balance_after":2100,"derivative":{"underlying":"Common Stock","underlying_shares":2100},"source":{"system":"sec-edgar","filing":"0001209191-23-031105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123031105/doc4.xml","form_type":"4"}},{"id":1885688,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2023-05-19T21:15:18.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":4290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 monthly installments beginning June 17, 2023."}],"balance_after":4290,"derivative":{"exercise_price":95.27,"expiration_date":"2033-05-17","underlying":"Common Stock","underlying_shares":4290},"source":{"system":"sec-edgar","filing":"0001209191-23-031105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123031105/doc4.xml","form_type":"4"}},{"id":1885335,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-05-19T20:05:31.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":13500,"derivative":{"exercise_price":17.11,"exercise_date":"2024-05-17","expiration_date":"2033-05-16","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001209191-23-030959","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919123030959/doc4.xml","form_type":"4"}},{"id":1885334,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T20:05:31.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":44500,"source":{"system":"sec-edgar","filing":"0001209191-23-030959","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919123030959/doc4.xml","form_type":"4"}},{"id":1908832,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-02T22:44:12.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":150437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025."}],"balance_after":150437,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":150437},"source":{"system":"sec-edgar","filing":"0001209191-23-026725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919123026725/doc4.xml","form_type":"4"}},{"id":2036695,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T23:07:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024."}],"balance_after":20000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-006351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919123006351/doc4.xml","form_type":"4"}},{"id":2127741,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2022-11-02T22:42:57.000Z","date":"2022-10-31","kind":"exercise","acquired":false,"shares":15000,"price":12.71,"value":190650.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted May 23, 2013 and vested monthly over one year."}],"balance_after":0,"derivative":{"exercise_price":12.71,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-055393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055393/doc4.xml","form_type":"4"}},{"id":2127740,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T22:42:57.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":15000,"price":114.7602,"value":1721403.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.21 to $115.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":203697,"source":{"system":"sec-edgar","filing":"0001209191-22-055393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055393/doc4.xml","form_type":"4"}},{"id":2127739,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T22:42:57.000Z","date":"2022-10-31","kind":"exercise","acquired":true,"shares":15000,"price":12.71,"value":190650.0,"ownership":{"direct":true},"balance_after":218697,"source":{"system":"sec-edgar","filing":"0001209191-22-055393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055393/doc4.xml","form_type":"4"}},{"id":2142819,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-05T23:00:31.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":5000,"price":110.5422,"value":552711.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $111.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":203697,"source":{"system":"sec-edgar","filing":"0001209191-22-052894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122052894/doc4.xml","form_type":"4"}},{"id":2260449,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-23T21:50:20.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":2.01,"expiration_date":"2032-05-20","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-22-020305","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122020305/form4.xml","form_type":"4"}},{"id":2260448,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-23T21:50:20.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001140361-22-020305","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122020305/form4.xml","form_type":"4"}},{"id":2262522,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2022-05-20T20:02:08.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":9724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 monthly installments beginning June 18, 2022."}],"balance_after":9724,"derivative":{"exercise_price":84.95,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":9724},"source":{"system":"sec-edgar","filing":"0001209191-22-030951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122030951/doc4.xml","form_type":"4"}},{"id":2269410,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T17:15:05.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":65000,"derivative":{"exercise_price":0.1875,"exercise_date":"2023-05-17","expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000819050-22-000072","document":"wf-form4_165282206394146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000081905022000072/wf-form4_165282206394146.xml","form_type":"4"}},{"id":2273744,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-05-13T00:24:59.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":9000,"derivative":{"exercise_price":21.38,"exercise_date":"2023-05-11","expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-22-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919122028694/doc4.xml","form_type":"4"}},{"id":2273743,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T00:24:59.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-22-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919122028694/doc4.xml","form_type":"4"}},{"id":2289924,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2022-04-27T21:26:07.000Z","date":"2022-04-25","kind":"exercise","acquired":false,"shares":15000,"price":6.66,"value":99900.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted May 23, 2012 and vested monthly over one year."}],"balance_after":0,"derivative":{"exercise_price":6.66,"expiration_date":"2022-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-025824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122025824/doc4.xml","form_type":"4"}},{"id":2289923,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-27T21:26:07.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":15000,"price":92.7595,"value":1391392.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.53 to $93.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":208697,"source":{"system":"sec-edgar","filing":"0001209191-22-025824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122025824/doc4.xml","form_type":"4"}},{"id":2289922,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-27T21:26:07.000Z","date":"2022-04-25","kind":"exercise","acquired":true,"shares":15000,"price":6.66,"value":99900.0,"ownership":{"direct":true},"balance_after":223697,"source":{"system":"sec-edgar","filing":"0001209191-22-025824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122025824/doc4.xml","form_type":"4"}},{"id":2417156,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:33:31.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023."}],"balance_after":20000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-006476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919122006476/doc4.xml","form_type":"4"}},{"id":2544924,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T22:34:53.000Z","date":"2021-10-07","kind":"sale","acquired":false,"shares":5000,"price":105.0587,"value":525293.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.23. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":208697,"source":{"system":"sec-edgar","filing":"0001209191-21-060283","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121060283/doc4.xml","form_type":"4"}},{"id":2670844,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T00:25:43.000Z","date":"2021-06-10","kind":"sale","acquired":false,"shares":10000,"price":100.2743,"value":1002743.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.04 to $100.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":213697,"source":{"system":"sec-edgar","filing":"0001209191-21-040445","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121040445/doc4.xml","form_type":"4"}},{"id":2670951,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T16:43:31.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":40000,"derivative":{"exercise_price":0.9,"exercise_date":"2022-06-14","expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000819050-21-000084","document":"wf-form4_162370339855730.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000081905021000084/wf-form4_162370339855730.xml","form_type":"4"}},{"id":2701340,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-22T00:50:25.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":3.64,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-21-005765","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021005765/edgar.xml","form_type":"4"}},{"id":2701339,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-22T00:50:25.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001179110-21-005765","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021005765/edgar.xml","form_type":"4"}},{"id":2703962,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2021-05-20T20:03:31.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":8833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 equal monthly installments beginning June 19, 2021."}],"balance_after":8833,"derivative":{"exercise_price":92.35,"exercise_date":"2021-06-19","expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":8833},"source":{"system":"sec-edgar","filing":"0001209191-21-034376","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121034376/doc4.xml","form_type":"4"}},{"id":2708576,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-05-19T01:22:44.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":9000,"derivative":{"exercise_price":18.27,"exercise_date":"2022-05-14","expiration_date":"2031-05-13","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-21-033852","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919121033852/doc4.xml","form_type":"4"}},{"id":2708575,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-19T01:22:44.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":37000,"source":{"system":"sec-edgar","filing":"0001209191-21-033852","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919121033852/doc4.xml","form_type":"4"}},{"id":2893984,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-28T02:53:04.000Z","date":"2021-01-26","kind":"sale","acquired":false,"shares":400,"price":120,"value":48000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":223697,"source":{"system":"sec-edgar","filing":"0001209191-21-005823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005823/doc4.xml","form_type":"4"}},{"id":2893983,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-28T02:53:04.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":1600,"price":120.0291,"value":192046.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power."}],"balance_after":224097,"source":{"system":"sec-edgar","filing":"0001209191-21-005823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005823/doc4.xml","form_type":"4"}},{"id":2923693,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T18:32:59.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":5967,"price":0.78,"value":4654.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs."}],"balance_after":18762,"source":{"system":"sec-edgar","filing":"0001062993-21-000139","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299321000139/form4.xml","form_type":"4"}},{"id":3029366,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-09-17T17:06:37.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options will vest 25% on September 15, 2021, and the remainder will vest in equal monthly installments over the following three years."}],"balance_after":60000,"derivative":{"exercise_price":0.8,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001062993-20-004555","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320004555/form4.xml","form_type":"4"}},{"id":3029365,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-17T17:06:37.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":11934,"price":0.81,"value":9666.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 15, 2020, the reporting person was granted 11,934 restricted stock units (\"RSUs\") in lieu of a portion of cash compensation as a director of Brickell Biotech, Inc.  The RSUs are scheduled to vest on December 31, 2020 and will be settled in the form of one share of common stock for each RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 15, 2020, the reporting person was granted 11,934 restricted stock units (\"RSUs\") in lieu of a portion of cash compensation as a director of Brickell Biotech, Inc.  The RSUs are scheduled to vest on December 31, 2020 and will be settled in the form of one share of common stock for each RSU."}],"balance_after":24729,"source":{"system":"sec-edgar","filing":"0001062993-20-004555","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320004555/form4.xml","form_type":"4"}},{"id":3031591,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-16T00:18:06.000Z","date":"2020-09-11","kind":"grant","acquired":true,"shares":1167.21,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 1,167.21 shares of the Issuer's Series X1 Convertible Preferred Stock, which will vest in equal monthly installments over two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer."}],"balance_after":1167.21,"derivative":{"exercise_price":500,"expiration_date":"2030-09-11","underlying":"Series X1 Convertible Preferred Stock","underlying_shares":1167.21},"source":{"system":"sec-edgar","filing":"0000899243-20-025172","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000089924320025172/doc4.xml","form_type":"4"}},{"id":3041947,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-09-02T16:22:39.000Z","date":"2020-08-31","kind":"exercise","acquired":false,"shares":692,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":692},"source":{"system":"sec-edgar","filing":"0001062993-20-004308","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320004308/form4.xml","form_type":"4"}},{"id":3041946,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-02T16:22:39.000Z","date":"2020-08-31","kind":"tax_withholding","acquired":false,"shares":8631,"price":0.94,"value":8113.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs."}],"balance_after":12795,"source":{"system":"sec-edgar","filing":"0001062993-20-004308","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320004308/form4.xml","form_type":"4"}},{"id":3041945,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-02T16:22:39.000Z","date":"2020-08-31","kind":"tax_withholding","acquired":false,"shares":346,"price":0.94,"value":325.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs."}],"balance_after":21426,"source":{"system":"sec-edgar","filing":"0001062993-20-004308","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320004308/form4.xml","form_type":"4"}},{"id":3041944,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-02T16:22:39.000Z","date":"2020-08-31","kind":"exercise","acquired":true,"shares":692,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."}],"balance_after":21772,"source":{"system":"sec-edgar","filing":"0001062993-20-004308","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320004308/form4.xml","form_type":"4"}},{"id":3070500,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-08-04T17:09:17.000Z","date":"2020-07-31","kind":"exercise","acquired":false,"shares":692,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020."}],"balance_after":692,"derivative":{"underlying":"Common Stock","underlying_shares":692},"source":{"system":"sec-edgar","filing":"0001062993-20-003648","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320003648/form4.xml","form_type":"4"}},{"id":3070499,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-04T17:09:17.000Z","date":"2020-07-31","kind":"tax_withholding","acquired":false,"shares":346,"price":0.92,"value":318.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs."}],"balance_after":21080,"source":{"system":"sec-edgar","filing":"0001062993-20-003648","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320003648/form4.xml","form_type":"4"}},{"id":3070498,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-04T17:09:17.000Z","date":"2020-07-31","kind":"exercise","acquired":true,"shares":692,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."}],"balance_after":21426,"source":{"system":"sec-edgar","filing":"0001062993-20-003648","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320003648/form4.xml","form_type":"4"}},{"id":3093902,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-07-02T14:01:56.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reporting person filed a Form 4 on June 5, 2020 which reported, among other transactions, the vesting on various dates of portions of a grant of RSUs made to the reporting person on February 14, 2020.  Column 9 of Table II of that Form 4 incorrectly reported the number of unvested RSUs remaining from that grant following each such vesting.  The number reported in this Column 9 of Table II of this Form 4 represents the correct number of unvested RSUs remaining from the February 14, 2020 grant following the vestings that were reported on the Form 4 filed on June 5, 2020, as well as the vesting that occurred on June 30, 2020 as reported on this Form 4."}],"balance_after":1384,"derivative":{"underlying":"Common Stock","underlying_shares":691},"source":{"system":"sec-edgar","filing":"0000911916-20-000144","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/819050/000091191620000144/edgar.xml","form_type":"4"}}],"next_cursor":"2020-07-02T14:01:56.000000Z,3093902"}